
Seres Auto - Wikipedia
Seres Auto (formerly SF Motors) [1] is an electric vehicle company of Chinese automotive manufacturer Seres Group (formerly Chongqing Sokon Industry Group [2][3]).
seres
SERES incorporates the spirit of exploration into a new global journey by introducing its products, redefining luxury with intelligence.
SERES - SERES Group
Feb 4, 2025 · SERES is a technology-based manufacturing enterprise with new energy vehicles as its core business. The business area of SERES covers R&D, manufacturing, sales & services of NEVs, …
Establishing a Better Microbiome for Better Health - Seres Therapeutics
Our mission is to transform the lives of patients worldwide with revolutionary live biotherapeutics. We are creating new treatments for medically vulnerable patient populations to prevent bacterial bloodstream …
Seres – EV, Motor
SF Motors, Inc., dba SERES, is a customer-oriented E-Powertrain technology development & manufacturing company. We drive the automotive energy iteration. We are a Silicon Valley-based …
2025 Seres 5 Review: Can A Chinese Newcomer Beat Tesla And
Apr 12, 2025 · Seres, formerly known as SF Motors, may be rooted in China, but it has a Silicon Valley presence and once had grand ambitions of selling cars in the U.S.
Seres: Pricing, Models, and History of the Innovative Electric Vehicle ...
Explore Seres, from brand history to model prices. Detailed analysis of the most affordable and premium Seres electric vehicles available on the market.
Seres wants to export 50,000 electric cars in 2024
Mar 22, 2024 · Seres Auto (formerly active as SF Motors) is a brand of the Chinese Sokon Group. Its origins date back to 2016 when Dongfeng and Sokon founded the company as a joint venture based …
First Look Review: The Seres 5 is an interesting mid-size SUV
Jun 1, 2024 · Chinese auto brand Seres (you’d recall SF Motors, based in California, which it was known earlier as) has begun introducing electric models worldwide. This year, the company plans to deliver …
Our Programs - Seres Therapeutics
Seres is developing live biotherapeutics that target the mucosal barrier-immune interface to promote protective responses in vulnerable patients, including those with chronic inflammatory diseases like …